The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma
Multiple myeloma (MM) represents a hematological neoplasia with an uncontrolled proliferation of malignant plasma cells and complex cytogenetic abnormalities. t(11;14) has emerged as a crucial genetic aberration and is one of the most common primary translocations in MM. Patients harboring t(11;14)...
Main Authors: | Martina Kleber, Ioannis Ntanasis-Stathopoulos, Evangelos Terpos |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-12-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/24/5829 |
Similar Items
-
CD20 expression: A risk stratification factor for newly diagnosed multiple myeloma with t(11;14)
by: Yuan Jian, et al.
Published: (2022-12-01) -
Evaluating the difference in clinical efficacy for t(11;14) multiple myeloma patients with CD20- or CD20+
by: ZHAO Weihong, HUANG Bintao, LIU Rui, XIANG Caixia
Published: (2023-09-01) -
The prognostic impact of t(11;14) in multiple myeloma: A real‐world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)
by: Kenneth JC Lim, et al.
Published: (2023-08-01) -
Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity
by: Katia Todoerti, et al.
Published: (2021-09-01) -
BCMA in Multiple Myeloma—A Promising Key to Therapy
by: Martina Kleber, et al.
Published: (2021-09-01)